Oxford BioMedica
Discover Realise
Investors

Investors

Oxford BioMedica has strong fundamentals as an investment proposition.

  • We have a valuable and focused pipeline of gene therapy products in development, addressing ophthalmology, central nervous system disorders and oncology
  • Our unique combination of capabilities and bioprocessing development activities are creating new revenue streams
  • Using gene and cell therapy as mainstream treatment is now closer than ever. We are well placed to benefit as rising interest boosts the value of companies in our sector

Click here to see our strategy for success
Click here to find out where you can meet us